JUSTINE WILSON: Open Payments
NPI 1114564036 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$541 in 30 payments from 10 companies in 2025. Trend: 2023 $973 · 2024 $1,089 · 2025 $541
Food & beverage: $541
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 7 | $124 |
| Novo Nordisk Inc | 5 | $94 |
| AstraZeneca Pharmaceuticals LP | 5 | $87 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $76 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $68 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| ABBVIE INC. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $17 |
| GlaxoSmithKline, LLC. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
Products named: JARDIANCE, MOUNJARO, CAPLYTA, AIRSUPRA, FARXIGA, Rybelsus, GEMTESA, Ozempic.
Industry payments across TX — which companies pay providers there.
